Skip to main content

Table 3 Analyses for prognostic indicators of Biochemical Recurrence-Free Survival

From: Long-term oncologic outcomes of radiotherapy combined with maximal androgen blockade for localized, high-risk prostate cancer

Variable

Biochemical Recurrence-Free Survival

Univariate analysis

Multivariate analysis

P Value

HR

P Value

HR

Age at diagnosis (years)

 ≤70 vs >70

0.339

――

0.147

――

Gland volume (mL)

 ≤33 vs >33

0.047

3.668

0.016

8.336

MAB

 Continuous vs Intermittent

0.031

1.492

0.018

3.217

PPB

 yes vs no

0.001

2.888

<0.001

5.126

Clinical stage

 ≤ T2c vs ≥T3a

0.041

4.737

0.013

6.142

Gleason score

 ≤7 vs ≥8

0.013

5.711

0.022

3.463

PSA at diagnosis (ng/mL)

 ≤10 vs 10~20 vs ≥20

0.019

2.622

0.001

6.334

Memorial Sloan-Kettering risk classification

 2~3 IS vs 1 HS vs 2 HS

0.027

1.772

0.009

3.643

PSA nadir (ng/mL)

 ≤1 vs >1

0.041

1.323

0.016

6.993

Time to PSA nadir (months)

 ≤3 vs >3

0.032

2.116

0.011

5.843

PSA doubling time (months)

 ≤12 vs >12

0.048

1.863

0.014

6.132

PSA decrease (%)

 <90 vs ≥90

0.006

3.677

<0.001

9.385

  1. MAB Maximal Androgen Blockade; PPB Permanent Prostate Brachytherapy; IS intermediate-Risk Standard; HS High-Risk Standard